An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.

被引：0
|
作者：
Aghajanian, Carol
Blank, Stephanie V.
Goff, Barbara Ann
Judson, Patricia Lynn
Nycum, Lawrence R.
Sovak, Mika A.
Yi, Jing
Husain, Amreen
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] NYU, Sch Med, New York, NY USA
[3] Univ Washington, Med Ctr, Seattle, WA 98195 USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[5] Forsyth Reg Canc Ctr, Winston Salem, NC USA
[6] Genentech Inc, San Francisco, CA 94080 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5054
引用
收藏
页数：1
相关论文
共 32 条
  • [1] UPDATED OVERALL SURVIVAL ANALYSIS IN OCEANS, A RANDOMIZED PHASE 3 TRIAL OF GEMCITABINE (G) plus CARBOPLATIN (C) AND BEVACIZUMAB (BV) OR PLACEBO (PL) FOLLOWED BY BV OR PL IN PLATINUM-SENSITIVE RECURRENT EPITHELIAL OVARIAN (ROC), PRIMARY PERITONEAL (PPC), OR FALLOPIAN TUBE CANCER (FTC)
    Aghajanian, C.
    Nycum, L. R.
    Goff, B.
    Nguyen, H.
    Husain, A.
    Blank, S. V.
    ANNALS OF ONCOLOGY, 2012, 23 : 319 - 319
  • [2] Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
    Aghajanian, C.
    Blank, S.
    Goff, B.
    Judson, P.
    Nycum, L.
    Sovak, M.
    Yi, J.
    Husain, A.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 773 - 773
  • [3] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [4] Independent radiologic review of OCEANS, a phase III trial of carboplatin, gemcitabine, and bevacizumab or placebo for the treatment of platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Aghajanian, C.
    Makhija, S.
    Rutherford, T.
    Sharma, S.
    Nycum, L.
    Sovak, M.
    Nguyen, H.
    Yi, J.
    Husain, A.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S30 - S31
  • [5] Safety Assessment of Niraparib Individualized Starting Dose in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: The Randomized, Double-Blind, Placebo-Controlled, Phase III NORA Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 13 - 14
  • [6] Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.
    Wang, Jing
    Wu, Xiaohua
    Zhu, Jianqing
    Yin, Rutie
    Yang, Jiaxin
    Huang, Qidan
    Wu, Lingying
    Liu, Ziling
    Gao, Yunong
    Wang, Danbo
    Lou, Ge
    Yang, Hongying
    Zhou, Qi
    Kong, Beihua
    Huang, Yi
    Chen, Lipai
    Li, Guiling
    An, Ruifang
    Tan, Tao
    Dong, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Efficacy and safety of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (NORA) with individualized starting dose: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase III trial
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Liu, Z.
    Gao, Y.
    Wang, D.
    Lou, G.
    Yang, H.
    Zhou, Q.
    Kong, B.
    Huang, Y.
    Chen, L.
    Li, G.
    An, R.
    Wang, K.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1335 - S1335
  • [8] A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer.
    Vergote, Ignace
    Heitz, Florian
    Buderath, Paul
    Powell, Matthew A.
    Sehouli, Jalid
    Lee, Christine M.
    Hamilton, Anne L.
    Fiorica, James
    Moore, Kathleen N.
    Teneriello, Michael
    Golden, Lisa
    Zhang, Wei
    Pitou, Celine
    Farrington, Daphne L.
    Bell-McGuinn, Katherine M.
    Wenham, Robert Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial
    Li, Ning
    Zhang, Youzhong
    Wang, Jing
    Zhu, Jianqing
    Wang, Li
    Wu, Xiaohua
    Yao, Desheng
    Wu, Qiang
    Liu, Jihong
    Tang, Junying
    Yin, Rutie
    Zhang, Guonan
    Lou, Ge
    An, Ruifang
    Xia, Xiaoping
    Li, Qingshui
    Zhu, Yaping
    Hong, Zheng
    Yang, Xinfeng
    Hu, Yuanjing
    Zhang, Xin
    Wan, Xiaoyun
    Qu, Jing
    Zhang, Ben
    Wu, Lingying
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S57 - S58
  • [10] Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Liu, Z.
    Gao, Y.
    Wang, D.
    Lou, G.
    Yang, H.
    Zhou, Q.
    Kong, B.
    Huang, Y.
    Chen, L.
    Li, G.
    An, R.
    Wang, K.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1160 - S1161
1234